8.43

1.75% -0.15

XBiotech Inc (XBIT)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

XBiotech Inc stock is currently priced at $8.43, with a 24-hour trading volume of 29,994. It has seen a -1.75% decreased in the last 24 hours and a +3.95% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $8.60 pivot point. If it approaches the $8.41 support level, significant changes may occur.

Previous Close:

$8.58

Open:

$8.53

24h Volume:

29,994

Market Cap:

$256.76M

Revenue:

$4.01M

Net Income/Loss:

$-24.56M

P/E Ratio:

-8.9681

EPS:

-0.94

Net Cash Flow:

$-19.09M

1W Performance:

+1.44%

1M Performance:

+3.95%

6M Performance:

+121.55%

1Y Performance:

+87.75%

1D Range:

$8.27

$8.53

52W Range:

$3.51

$9.96

XBiotech Inc Stock (XBIT) Company Profile

Name

XBiotech Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

512-386-2900

Address

8201 East Riverside Drive, Building 4 Suite 100, Austin, TX

Employee

Twitter

@xbiotech_usa

Next Earnings Date

2024-05-08

Latest SEC Filings

XBIT's Discussions on Twitter

XBiotech Inc Stock (XBIT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-14-19	Initiated	Piper Jaffray	Overweight
Apr-21-17	Downgrade	Noble Financial	Buy → Hold
Jun-28-16	Reiterated	Noble Financial	Buy

XBiotech Inc Stock (XBIT) Latest News

National Bank of Canada FI Acquires Shares of 24347 XBiotech Inc. (NASDAQ:XBIT) - Defense World

Defense World

XBiotech Inc Stock (XBIT) Financials Data

XBiotech Inc (XBIT) Revenue 2024

XBIT reported a revenue (TTM) of $4.01 million for the quarter ending December 31, 2022, a -78.20% decline year-over-year.

XBiotech Inc (XBIT) Net Income 2024

XBIT net income (TTM) was -$24.56 million for the quarter ending December 31, 2023, a +25.36% increase year-over-year.

XBiotech Inc (XBIT) Cash Flow 2024

XBIT recorded a free cash flow (TTM) of -$19.09 million for the quarter ending December 31, 2023, a -23.87% decrease year-over-year.

XBiotech Inc (XBIT) Earnings per Share 2024

XBIT earnings per share (TTM) was -$0.82 for the quarter ending December 31, 2023, a +24.07% growth year-over-year.

XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.